Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2001-11

AUTHORS

K. F. Petersen, J. T. Sullivan

ABSTRACT

AIMS/HYPOTHESIS: To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans. METHODS: The study was conducted as a two-dose [Low Dose Bay 27-9955 70 mg, (n = 6), High Dose Bay 27-9955 200 mg, (n = 8)], double blind, placebo controlled, crossover study. Basal glucose production was measured after an overnight fast with [6,6-2H]. At 0 min Bay 27-9955 or placebo was administered and at 120 min an infusion of somatostatin [0.1 microg x (kg x min)(-1)], insulin [24 pmol x (m2 x min)(-1)] and glucagon [3 ng x (kg x min)(-1)] was initiated. RESULTS: Basal plasma glucose concentrations were about 5 mmol/l and basal rates of glucose production were about 13 micromol x (kg x min)(-1). During the hyperglucagonaemic period, plasma glucagon concentrations doubled to 100 pg/ml, plasma glucose concentration increased by 75 % to a peak of about 10 mmol/l and glucose production doubled to about 23 micromol x (kg x min)(-1) (p < 0.0001 vs basal). In the High Dose Group these effects of glucagon were markedly blunted, plasma glucose concentrations were 7.6 +/- 1.1 mmol/l (p = 0.012 vs placebo) and rates of glucose production increased minimally to 15.3 +/- 1.9 micromol x (kg-min)(-1) (p < 0.0003 vs placebo]. In the Low Dose Group, there was a proportional decrease in the effects of Bay 27-9955 on these parameters. CONCLUSION/INTERPRETATION: Bay 27-9955 is an effective and safe glucagon antagonist in humans. Given the potentially important role of glucagon in increasing glucose production and gluconeogenesis in patients with Type II (non-insulin-dependent) diabetes mellitus this agent could represent an innovative class of therapeutic agents for the disease. More... »

PAGES

2018-2024

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s001250100006

DOI

http://dx.doi.org/10.1007/s001250100006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021091422

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11719833


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biphenyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucagon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycated Hemoglobin A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hormone Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Glucagon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reference Values", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Somatostatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petersen", 
        "givenName": "K. F.", 
        "id": "sg:person.014300404317.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014300404317.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419670.d", 
          "name": [
            "Bayer Pharmaceuticals, West Haven, CT, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sullivan", 
        "givenName": "J. T.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1172/jci109693", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002337846"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci118460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005371133"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0026-0495(89)90129-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015417802"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197808312990901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015987061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci115997", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017493040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.49.12.2063", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019256166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci108596", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022177423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000441-197008000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034050352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000441-197008000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034050352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0304-4165(73)90067-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037036142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0304-4165(73)90067-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037036142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci106297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040356782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci111533", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048666084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem-48-1-171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064310374"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.17.7.415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070731523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.36.3.274", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070735218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.44.2.185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070737496"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-11", 
    "datePublishedReg": "2001-11-01", 
    "description": "AIMS/HYPOTHESIS: To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans.\nMETHODS: The study was conducted as a two-dose [Low Dose Bay 27-9955 70 mg, (n = 6), High Dose Bay 27-9955 200 mg, (n = 8)], double blind, placebo controlled, crossover study. Basal glucose production was measured after an overnight fast with [6,6-2H]. At 0 min Bay 27-9955 or placebo was administered and at 120 min an infusion of somatostatin [0.1 microg x (kg x min)(-1)], insulin [24 pmol x (m2 x min)(-1)] and glucagon [3 ng x (kg x min)(-1)] was initiated.\nRESULTS: Basal plasma glucose concentrations were about 5 mmol/l and basal rates of glucose production were about 13 micromol x (kg x min)(-1). During the hyperglucagonaemic period, plasma glucagon concentrations doubled to 100 pg/ml, plasma glucose concentration increased by 75 % to a peak of about 10 mmol/l and glucose production doubled to about 23 micromol x (kg x min)(-1) (p < 0.0001 vs basal). In the High Dose Group these effects of glucagon were markedly blunted, plasma glucose concentrations were 7.6 +/- 1.1 mmol/l (p = 0.012 vs placebo) and rates of glucose production increased minimally to 15.3 +/- 1.9 micromol x (kg-min)(-1) (p < 0.0003 vs placebo]. In the Low Dose Group, there was a proportional decrease in the effects of Bay 27-9955 on these parameters.\nCONCLUSION/INTERPRETATION: Bay 27-9955 is an effective and safe glucagon antagonist in humans. Given the potentially important role of glucagon in increasing glucose production and gluconeogenesis in patients with Type II (non-insulin-dependent) diabetes mellitus this agent could represent an innovative class of therapeutic agents for the disease.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s001250100006", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2423996", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2495379", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2436076", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "name": "Effects of a novel glucagon receptor antagonist (Bay 27\u20139955) on glucagon-stimulated glucose production in humans", 
    "pagination": "2018-2024", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "647d919d8b75aff2d85735a8acd01825feae66aaeada324b20cf8963febbfa8a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11719833"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0006777"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s001250100006"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021091422"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s001250100006", 
      "https://app.dimensions.ai/details/publication/pub.1021091422"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89793_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs001250100006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      59 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s001250100006 schema:about N08eb75e9ab0d4722bc5894cb6f9172a6
2 N167e0b296ba4401188ddc3eabfdd12cf
3 N1bca87f567cc454882a143de99382d3b
4 N428001f0e35a4cd5b96d88282132d0e5
5 N5d749b7562e54912b19e262f86d1be60
6 N6604e796010a4d6494d1fc9f47017d00
7 N678418430b344c4eb437e228c39a7409
8 N74dd74a4daf9493c98fe4f4cb8a8b550
9 N84a5deb95e5c46db92e683880a6470dc
10 N8f7ef724c6184b708ddcee8d2bc1090f
11 N91db5b2fc2c74e66b8d9ddfec0804a5b
12 Nbc0f0198df304a348bec03ba65af4ba1
13 Nc866dc45986c43919ccdb1a98d0c029a
14 Ne4c31dc4ca5f491eb5bbe1976732beef
15 Nf2e85d817eae4abdba61787f6a0ba501
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N283e2f0fe6424d84a19dd6dc125cdfc7
19 schema:citation https://doi.org/10.1016/0026-0495(89)90129-7
20 https://doi.org/10.1016/0304-4165(73)90067-6
21 https://doi.org/10.1056/nejm197808312990901
22 https://doi.org/10.1097/00000441-197008000-00001
23 https://doi.org/10.1172/jci106297
24 https://doi.org/10.1172/jci108596
25 https://doi.org/10.1172/jci109693
26 https://doi.org/10.1172/jci111533
27 https://doi.org/10.1172/jci115997
28 https://doi.org/10.1172/jci118460
29 https://doi.org/10.1210/jcem-48-1-171
30 https://doi.org/10.2337/diab.17.7.415
31 https://doi.org/10.2337/diab.36.3.274
32 https://doi.org/10.2337/diab.44.2.185
33 https://doi.org/10.2337/diabetes.49.12.2063
34 schema:datePublished 2001-11
35 schema:datePublishedReg 2001-11-01
36 schema:description AIMS/HYPOTHESIS: To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans. METHODS: The study was conducted as a two-dose [Low Dose Bay 27-9955 70 mg, (n = 6), High Dose Bay 27-9955 200 mg, (n = 8)], double blind, placebo controlled, crossover study. Basal glucose production was measured after an overnight fast with [6,6-2H]. At 0 min Bay 27-9955 or placebo was administered and at 120 min an infusion of somatostatin [0.1 microg x (kg x min)(-1)], insulin [24 pmol x (m2 x min)(-1)] and glucagon [3 ng x (kg x min)(-1)] was initiated. RESULTS: Basal plasma glucose concentrations were about 5 mmol/l and basal rates of glucose production were about 13 micromol x (kg x min)(-1). During the hyperglucagonaemic period, plasma glucagon concentrations doubled to 100 pg/ml, plasma glucose concentration increased by 75 % to a peak of about 10 mmol/l and glucose production doubled to about 23 micromol x (kg x min)(-1) (p < 0.0001 vs basal). In the High Dose Group these effects of glucagon were markedly blunted, plasma glucose concentrations were 7.6 +/- 1.1 mmol/l (p = 0.012 vs placebo) and rates of glucose production increased minimally to 15.3 +/- 1.9 micromol x (kg-min)(-1) (p < 0.0003 vs placebo]. In the Low Dose Group, there was a proportional decrease in the effects of Bay 27-9955 on these parameters. CONCLUSION/INTERPRETATION: Bay 27-9955 is an effective and safe glucagon antagonist in humans. Given the potentially important role of glucagon in increasing glucose production and gluconeogenesis in patients with Type II (non-insulin-dependent) diabetes mellitus this agent could represent an innovative class of therapeutic agents for the disease.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N23b86e11412a4f989400c48579cc7070
41 Nf6b9c16c996940caa1968dc77d6788f8
42 sg:journal.1001482
43 schema:name Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans
44 schema:pagination 2018-2024
45 schema:productId N12c3484292fa400aa6b09e8bb6dfc9a9
46 N531bc274fbef4f9fafe9adb94317f32f
47 N738d9250c7d5457e83c5357bb5051405
48 Nc83dc4fedfb341e6bc5e00d46d9a23c6
49 Nd07e74c3ddb64409a96eb96131254c41
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021091422
51 https://doi.org/10.1007/s001250100006
52 schema:sdDatePublished 2019-04-11T09:53
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher Nda761d98525d4a41878efd57bbfbbf89
55 schema:url https://link.springer.com/10.1007%2Fs001250100006
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N08eb75e9ab0d4722bc5894cb6f9172a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Glucagon
61 rdf:type schema:DefinedTerm
62 N12c3484292fa400aa6b09e8bb6dfc9a9 schema:name doi
63 schema:value 10.1007/s001250100006
64 rdf:type schema:PropertyValue
65 N167e0b296ba4401188ddc3eabfdd12cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Male
67 rdf:type schema:DefinedTerm
68 N1bca87f567cc454882a143de99382d3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Reference Values
70 rdf:type schema:DefinedTerm
71 N23b86e11412a4f989400c48579cc7070 schema:volumeNumber 44
72 rdf:type schema:PublicationVolume
73 N283e2f0fe6424d84a19dd6dc125cdfc7 rdf:first sg:person.014300404317.81
74 rdf:rest Nbe56c0f2c98f47a1ac92b72e91f773b9
75 N428001f0e35a4cd5b96d88282132d0e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Adult
77 rdf:type schema:DefinedTerm
78 N531bc274fbef4f9fafe9adb94317f32f schema:name dimensions_id
79 schema:value pub.1021091422
80 rdf:type schema:PropertyValue
81 N5d749b7562e54912b19e262f86d1be60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Humans
83 rdf:type schema:DefinedTerm
84 N6604e796010a4d6494d1fc9f47017d00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Placebos
86 rdf:type schema:DefinedTerm
87 N678418430b344c4eb437e228c39a7409 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Blood Glucose
89 rdf:type schema:DefinedTerm
90 N738d9250c7d5457e83c5357bb5051405 schema:name nlm_unique_id
91 schema:value 0006777
92 rdf:type schema:PropertyValue
93 N74dd74a4daf9493c98fe4f4cb8a8b550 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Somatostatin
95 rdf:type schema:DefinedTerm
96 N7c7531ec4b4240e3989b888087c0b29b schema:affiliation https://www.grid.ac/institutes/grid.419670.d
97 schema:familyName Sullivan
98 schema:givenName J. T.
99 rdf:type schema:Person
100 N84a5deb95e5c46db92e683880a6470dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Time Factors
102 rdf:type schema:DefinedTerm
103 N8f7ef724c6184b708ddcee8d2bc1090f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Biphenyl Compounds
105 rdf:type schema:DefinedTerm
106 N91db5b2fc2c74e66b8d9ddfec0804a5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Glycated Hemoglobin A
108 rdf:type schema:DefinedTerm
109 Nbc0f0198df304a348bec03ba65af4ba1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Kinetics
111 rdf:type schema:DefinedTerm
112 Nbe56c0f2c98f47a1ac92b72e91f773b9 rdf:first N7c7531ec4b4240e3989b888087c0b29b
113 rdf:rest rdf:nil
114 Nc83dc4fedfb341e6bc5e00d46d9a23c6 schema:name readcube_id
115 schema:value 647d919d8b75aff2d85735a8acd01825feae66aaeada324b20cf8963febbfa8a
116 rdf:type schema:PropertyValue
117 Nc866dc45986c43919ccdb1a98d0c029a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Hormone Antagonists
119 rdf:type schema:DefinedTerm
120 Nd07e74c3ddb64409a96eb96131254c41 schema:name pubmed_id
121 schema:value 11719833
122 rdf:type schema:PropertyValue
123 Nda761d98525d4a41878efd57bbfbbf89 schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 Ne4c31dc4ca5f491eb5bbe1976732beef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Receptors, Glucagon
127 rdf:type schema:DefinedTerm
128 Nf2e85d817eae4abdba61787f6a0ba501 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Insulin
130 rdf:type schema:DefinedTerm
131 Nf6b9c16c996940caa1968dc77d6788f8 schema:issueNumber 11
132 rdf:type schema:PublicationIssue
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
137 schema:name Clinical Sciences
138 rdf:type schema:DefinedTerm
139 sg:grant.2423996 http://pending.schema.org/fundedItem sg:pub.10.1007/s001250100006
140 rdf:type schema:MonetaryGrant
141 sg:grant.2436076 http://pending.schema.org/fundedItem sg:pub.10.1007/s001250100006
142 rdf:type schema:MonetaryGrant
143 sg:grant.2495379 http://pending.schema.org/fundedItem sg:pub.10.1007/s001250100006
144 rdf:type schema:MonetaryGrant
145 sg:journal.1001482 schema:issn 0012-186X
146 1432-0428
147 schema:name Diabetologia
148 rdf:type schema:Periodical
149 sg:person.014300404317.81 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
150 schema:familyName Petersen
151 schema:givenName K. F.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014300404317.81
153 rdf:type schema:Person
154 https://doi.org/10.1016/0026-0495(89)90129-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015417802
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/0304-4165(73)90067-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037036142
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1056/nejm197808312990901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015987061
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1097/00000441-197008000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034050352
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1172/jci106297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040356782
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1172/jci108596 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022177423
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1172/jci109693 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002337846
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1172/jci111533 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048666084
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1172/jci115997 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017493040
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1172/jci118460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005371133
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1210/jcem-48-1-171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064310374
175 rdf:type schema:CreativeWork
176 https://doi.org/10.2337/diab.17.7.415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070731523
177 rdf:type schema:CreativeWork
178 https://doi.org/10.2337/diab.36.3.274 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070735218
179 rdf:type schema:CreativeWork
180 https://doi.org/10.2337/diab.44.2.185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070737496
181 rdf:type schema:CreativeWork
182 https://doi.org/10.2337/diabetes.49.12.2063 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019256166
183 rdf:type schema:CreativeWork
184 https://www.grid.ac/institutes/grid.419670.d schema:alternateName Bayer (United States)
185 schema:name Bayer Pharmaceuticals, West Haven, CT, USA, US
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
188 schema:name Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut, USA, US
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...